10578-75-3

Basic information

• Product Name: 2-(BENZYLOXY)-1-ETHANAMINE HYDROCHLORIDE
• Synonyms: AMINOETHYLBENZYL ETHER HYDROCHLORIDE;2-(BENZYLOXY)-1-ETHANAMINE HYDROCHLORIDE;2-(Benzyloxy)-1-ethaneamineHCl;2-(Benzyloxy)-1-ethaneaminehydrochloride;Aminoethylbenzyl ether hydrochloride 90%;Aminoethylbenzyletherhydrochloride90%;2-(benzyloxy)ethanamine hydrochloride;[2-(benzyloxy)ethyl]amine hydrochloride
• CAS NO: 10578-75-3
• Molecular Formula: C₉H₁₃NO*ClH
• Molecular Weight: 187.67
• Product Categories: Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 10578-75-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 142 °C
• Boiling Point: 240.6 °C at 760 mmHg
• Flash Point: 84.9 °C
• Appearance: /
• Vapor Pressure: 0.0376mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-(BENZYLOXY)-1-ETHANAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(BENZYLOXY)-1-ETHANAMINE HYDROCHLORIDE(10578-75-3)
• EPA Substance Registry System: 2-(BENZYLOXY)-1-ETHANAMINE HYDROCHLORIDE(10578-75-3)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36-43
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 10578-75-3(Hazardous Substances Data)

Usage

Uses

2-Benzyloxyethylamine Hydrochloride is used to synthesize single and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles with anti-HIV-1 activities.

InChI:InChI=1/C9H13NO.ClH/c10-6-7-11-8-9-4-2-1-3-5-9;/h1-5H,6-8,10H2;1H

Upstream product

• 2002-24-6 2-amino-ethanol hydrochloride 
• 100-44-7 benzyl chloride 
• 634925-24-9 tert-butyl (2-(benzyloxy)ethyl)carbamate 

Downstream Products

• 298712-66-0 N-[2-(benzyloxy)ethyl]hexadecylamide 
• 350689-55-3 N-[2-(benzyloxy)ethyl]-7-(F-octyl)heptanamide 
• 78407-19-9 [(2-isocyanatoethoxy)methyl]benzene 
• 1093643-63-0 N-(2-benzyloxy-ethyl)-2-(1-hydroxy-1,3-dihydro-benzo[c][1,2]oxaborol-7-yloxy)-acetamide 
• 1207634-76-1 N-[2-(benzyloxy)ethyl]-1H-imidazole-1-carboxamide 
• 155769-05-4 2-chloro-N-[2-(phenylmethoxy)ethyl]adenosine 
• 634925-25-0 N-[2-(benzyloxy)ethyl]-2-chloro-5,6-dimethyl-3-nitropyridin-4-amine 
• 298712-67-1 N-[2-(benzyloxy)ethyl]hexadecylamine 
• 350689-56-4 methyl N-[2-(benzyloxy)ethyl]-N-[7-(F-octyl)heptyl]-11-carboxamidoundecanoate 
• 350689-58-6 N-[2-(benzyloxy)ethyl]-7-(F-octyl)heptylamine 
• 298712-73-9 N¹,N²⁴-bis[2-(benzyloxy)ethyl]-1,24-tetracosanediamide 

Relevant articles and documents

A method for the production of primary amines

The invention relates to the field of chemical industry and particularly relates to a method for preparing primary amine by using the raw materials including halogenated hydrocarbon (or hydrocarbon alcohol sulfonate) and ammonia water (or formamide). The method comprises the following three steps: (1) imidization: 3,4-diarylfuran-2,5-diketone (I) reacts with ammonia (or formamide) and the like to obtain 3,4-diaryl-1H-pyrrole-2,5-diketone (II); (2) N-hydrocarbylation: 3,4-diaryl-1H-pyrrole-2,5-diketone (II) generates an N-hydrocarbylation reaction with halogenated hydrocarbon (or hydrocarbon alcohol sulfonate) in the presence of alkali to obtain N-hydrocarbyl-3,4-diaryl-1H-pyrrole-2,5-diketone (III); and (3) hydrolysis: N-hydrocarbyl-3,4-diaryl-1H-pyrrole-2,5-diketone (III) is subjected to alkali hydrolysis to obtain primary amine and the generated 2,3-diaryl maleate is subjected to acid treatment and automatic ring closing to form 3,4-diaryl furan-2,5-diketone (I) which is subjected to imidization and directly applied to the N-hydrocarbylation reaction. The method provided by the invention has the characteristics that the 3,4-diaryl furan-2,5-diketone can be circularly used at a high recovery rate, the molar ratio of the raw materials is low, and the yield of the product primary amine is high.

1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF

A 1,5-naphthyridine derivative represented by Formula [1] (in which R1, R2, R3, R4 and R5 represent a hydrogen atom, -L-Z (in which Z represents a non-aromatic heterocyclic group or the like; and L re

Dipeptide inhibitors of protein farnesyltransferase

The present invention provides compounds having the structure represented by formula (I). Also provided is a method of treating cancer, restenosis, atherosclerosis, or psoriasis or preventing restenosis, and a pharmaceutical composition comprising a compo